Publication | Open Access
Potent antagonism by BIM‐23056 at the human recombinant somatostatin sst<sub>5</sub> receptor
35
Citations
5
References
1996
Year
ImmunologyPharmacotherapyExperimental PharmacologyCellular PhysiologyMolecular PharmacologyPotent AntagonismLinear Octapeptide Bim-23056Surmountable AntagonistCell SignalingMolecular SignalingMolecular PhysiologyBiochemistryReceptor (Biochemistry)Cho-k1 CellsPharmacologySignal TransductionFunctional SelectivityPhysiologySystems BiologyMedicine
We have investigated the effects of somatostatin (SRIF) and the linear octapeptide BIM-23056 on changes in intracellular calcium ion concentration ([Ca2+]i) and on the formation of inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) in CHO-K1 cells transfected with the human recombinant SRIF sst5 receptor. SRIF elicited concentration-dependent increases in [Ca2+]i, with a pEC50 of 7.02 +/- 0.06, while BIM-23056 (1 x 10(-7) M) behaved not as an agonist but as a potent, surmountable antagonist of these increases in [Ca2+]i. The SRIF concentration-effect curve for increases in [Ca2+]i was shifted rightward producing an estimated pKB for the antagonist of 8.0. BIM-23056 (1 x 10(-7) M) also significantly attenuated Ins(1,4,5)P3 increases due to SRIF, but had no effect on either basal or uridine 5'-triphosphate (UTP) (1 x 10(-4) M) stimulated increases in the levels of [Ca2+]i or Ins(1,4,5)P3.
| Year | Citations | |
|---|---|---|
Page 1
Page 1